CoronoVac is a non-viable vaccine for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). Nowadays, there has been vaccination program for at-risk groups and older adults in Turkey. We here present 72-year-old male psoriasis patient who developed generalized pustular psoriasis flare after administration of CoronoVac. The COVID-PCR test was negative and investigations for flare etiology were all normal. He was first (to the best of our knowledge) psoriasis patient who developed an erythrodermic flare after the first dose of CoronaVac vaccine.

Background Alopecia areata (AA) is a common autoimmune non-scarring type of hair loss characterized by round patches on the scalp or body. AA is the second most common form of hair loss after male-pattern baldness in men, and female-pattern baldness in women. Aim of the study This study aims to examine the correlation between trichoscopic patterns and AA severity, evaluated by the Severity of Alopecia Tool (SALT) score, and to analyze the impact of demographic and clinical factors on treatment outcomes. Patients and methods A prospective cross-sectional single-center study was conducted involving 303 patients with AA, assessing the relationships between trichoscopic findings, clinical features, treatment responses, and SALT scores. Results Our cohort comprised 50.83% females and 49.17% males, ranging in age from 6 months to 84 years, with a mean age of 23.67 ± 14.79 years and an average disease onset at 21.68 (± 14.30) years. Localized and Multiple patchy AA were the most observed subtypes, with ophiasis, alopecia universalis, and totalis being less frequent. Small vellus hairs, exclamation mark hair, and coudability hair emerged as prevalent trichoscopic findings. A significant prevalence of comorbidities (82.18%) was observed, particularly micronutrient deficiencies, autoimmune and endocrine disorders, and atopic diseases. Key predictors of more severe AA, as indicated by higher SALT scores, include prolonged disease duration, nail involvement, and neuropsychiatric comorbidities. Shorter disease duration was correlated with active disease markers such as broken hairs, black dots, yellow dots, and exclamation mark hair. Markers like cumulus-like white dots and v-sign correlated with severe disease stages, whereas pigtail hairs, small vellus hairs, and upright regrowing hairs indicated new hair growth or positive treatment responses. Conclusion Trichoscopy proves crucial for assessing AA severity and treatment efficacy, facilitating personalized treatment approaches and improving patient management outcomes.

Background/objective: Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting apocrine gland areas, characterized by painful nodules and abscesses that may result in sinus tracts and scarring. The global prevalence of HS is increasing due to heightened awareness, improved diagnostic methods, rising obesity rates, and higher smoking prevalence. This study aimed to describe the epidemiological, clinical, and comorbid characteristics of HS patients.Methodology: This retrospective descriptive cross-sectional study included 193 outpatients aged between 15 and 73 years who visited a tertiary HS clinic between 2017 and 2022. Demographic, clinical, and comorbid characteristics were recorded and analyzed using chi-square and ordinal regression methods.Results: The mean age was 34.5 ± 12.1 years, with a mean disease duration of 5.9 ± 6.7 years. According to the Hurley classification, 61.1, 24.4, and 14.5% were stages I, II, and III, respectively. Comorbidities were present in 48.2% of patients, with psychiatric disorders (19.2%), diabetes mellitus (14%), and hypertension (9.3%) being most common. Disease duration, smoking, male gender, and atypical localization were associated with increased disease severity.Conclusion: Geographic and cultural factors influence the prevalence, severity, and management of HS, necessitating tailored treatment. Effective management requires multidisciplinary screening for early detection and prevention of comorbidities, including psychiatric disorders, cardiovascular conditions, and metabolic syndrome.

Non-segmental vitiligo (NSV) is a chronic autoimmune skin disease marked by melanocyte loss and depigmented macules. While clinical features are well recognized, immunohistological correlates such as Melan-A expression and CD8⁺ T-cell infiltration remain undercharacterized. To examine the clinical, histological, and immunohistochemical features of NSV, with a focus on their relationship to disease severity. In this prospective case-control study, 25 NSV patients and 25 matched healthy controls were evaluated using standardized scoring systems (VASI, VIDA, VETF, VETI). Biopsies from lesional, marginal, and normal skin underwent immunohistochemical staining for Melan-A and CD8⁺ T cells. Histopathological changes were graded using a structured scoring system. Lesional skin exhibited significant melanocyte loss (Melan-A⁺ median: 5 [IQR: 3–8]) and elevated CD8⁺ T-cell infiltration (median: 15 [10–18]) compared to controls (p < 0.001). Marginal zones showed intermediate values, indicating subclinical immune activation. CD8⁺ infiltration positively correlated with VASI (r = 0.53), while Melan-A expression showed a negative correlation (r = − 0.55). Both markers were independent predictors of disease severity. NSV exhibits a spatial immunohistological gradient, where melanocyte loss and CD8⁺ T-cell infiltration parallel clinical severity. The integration of immunophenotyping with clinical scoring provides a novel biomarker strategy for personalized therapy.

Background: Down syndrome (DS), a common chromosomal anomaly caused by trisomy of chromosome 21, is characterized by a broad spectrum of phenotypic characteristics across multiple organ systems, including cardiac defects and leukemia. Dermatological findings are prevalent among individuals with DS; however, these issues are frequently underrecognized and inadequately researched, resulting in a significant gap in the provision of comprehensive healthcare strategies. Given the increased life expectancy of patients with DS and delayed manifestation of many dermatoses, physicians are increasingly encountering dermatological findings in this population.Objective: This study aimed to assess the prevalence and types of dermatological findings in individuals with DS, compare them with those in a control group, and emphasize the necessity of incorporating dermatological evaluations into routine health monitoring.Methods: This prospective cross‐sectional study was conducted from June 2023 to June 2024 and involved 100 genetically confirmed individuals with DS and 100 age‐ and sex‐matched controls. Comprehensive demographic, clinical, and karyotype data were collected for the DS group, and all the participants underwent detailed morphological evaluations.Results: The DS group had a mean age of approximately 6.37 years, whereas the controls were around 7 years old, with no significant differences in age or sex distribution between the groups. Karyotype analysis showed that trisomy 21 was present in 92% of the cases, mosaicism in 6%, and translocation in 2%. Common dermatological findings in the DS group included xerosis cutis (49%), thin and sparse hair (48%), dental caries (34%), delayed tooth eruption (28%), nail dystrophy (25%), fissured tongue (23%), and cheilitis (18%). Significant differences were noted in the prevalence of scabies, bacterial infections, and café au lait macules between the DS and control groups (p < 0.01). Dysmorphic findings in the DS group included epicanthal folds (97%), upslanted palpebral fissures (97%), brachycephaly (91%), and single transverse palmar crease (89%). Significant gender differences were noted in the prevalence of brachycephaly and the sandal gap (p < 0.01).Conclusions: This study highlights the importance of regular dermatological care in enhancing the health management and quality of life of individuals with DS due to the prevalence and variability of dermatological conditions.

Background: Ten-year survival and retention rate data on biologics are extremely limited, and there is a need to evaluate these metrics based on real-world data as well as on the results of clinical studies. Objective: The objective of this study was to assess the long-term survival rates of adalimumab and infliximab in real-life practice. Methods: This study is based on data from the Turkish Psoriasis Registry and the digital records of the Medical School of Bezmialem Vakif University. Baseline data including demographic characteristics, duration of treatment, use of combination treatments, modified regimens, and reasons for treatment termination were extracted. Results: In total, 404 patients (228 on adalimumab and 176 on infliximab) treated between July 1, 2005, and December 31, 2020, were identified. The retention rate was 7.4% for infliximab and 3.5% for adalimumab after 10 years (p = 0.85). Conclusions: The efficacy of infliximab and adalimumab diminishes over time. There were no significant differences in the retention rate between the two drugs, but the survival time was longer for infliximab according to Kaplan-Meier analysis.